Cardiac 123I-MIBG uptake in De novo Brazilian patients with Parkinson's disease without clinically defined dysautonomia;Cintilografia miocárdica comu 123I-MIBG em pacientes Brasileiros com doença de Parkinson recentemente diagnosticada sem disautonomia clinicamente manifesta

Arquivos de Neuro-Psiquiatria

Volumn 72, Issue 6, 2014, Pages 430-434

  Leite, Marco Antonio Araujo ^a   Nascimento, Osvaldo J M ^a   Pereira, João Santos ^b   Amaral, Clayton ^a   Mesquita, Cláudio T ^a,e   Azevedo, Jader C ^a,e   de Brito, Adriana S X ^c   Pedras, Felipe Villela ^d  

^a HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Hospital Barra D'Or   (Brazil)

^d Villela Pedras Nuclear Medicine Clinic   (Brazil)

^e HOSPITAL PRÓ CARDÍACO   (Brazil)

Author keywords

3 iodobenzylguanidine; Denervation; Dysautonomia; Parkinson's disease; Radionuclide imaging

Indexed keywords

META IODO BENZYL GUANIDINE IODINE 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE;

ADRENERGIC TRANSMISSION; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; DOPPLER ECHOCARDIOGRAPHY; DYSAUTONOMIA; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PARKINSON DISEASE; RETROSPECTIVE STUDY; UNIFIED PARKINSON DISEASE RATING SCALE; VALSALVA MANEUVER; BRAZIL; CHI SQUARE DISTRIBUTION; DIAGNOSTIC USE; HEART; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; REFERENCE VALUE; REPRODUCIBILITY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNAPTIC TRANSMISSION;

3-IODOBENZYLGUANIDINE; AGED; BRAZIL; CHI-SQUARE DISTRIBUTION; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PARKINSON DISEASE; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84903304697     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/0004-282X20140042     Document Type: Article

References (29)

1. Fahn, S, Jankovic, J, Hallett, M. Clinical overview and phenomenology of movement disorders. In Fahn, S, Jankovic, J, Hallett M (Eds). Principles and practice of Movement disorders. Second edition. Saunders. Edinburgh. 2011:1.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
3. Cosentino C, Nuñez Y, Torres L. Frequency of non-motor symptoms in Peruvian patients with Parkinson's disease. Arq Neuropsiquiatr 2013;71:216-219.
4. Barbosa, ER. Non-motor symptoms in Parkinson's disease. Nonmotor symptoms in Parkinson's disease. Arq. Neuro-Psiquiatr 2013;71:203-204.
5. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003;110:517-536.
6. Chaudhuri, K R, Prieto-Jurcynska, C, Naidu, Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the Nonmotor Symptoms Questionnaire. Mov Disord 2010;25:704-709.
7. Chaudhurim KR, Odin P, Antonini A, Martinez-Martin P. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011;17:717-723.
8. Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009;66:167-172.
9. Goldstein DS, Orimo S. Cardiac sympathetic neuroimaging: summary of the first International Symposium. Clin Auton Res 2009;19:137-148.
10. Carrio I. Cardiac neurotransmisson imaging. J Nucl Med 2001;42:1062-1076.
11. http://www.ncbi.nlm.nih.gov/pubmed/?term=mibg+in+parkinson +disease on January 18, 2014 at 16:48h.
12. Leite MAA, Nascimento OJM. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 2010;17:9.
13. Druschky, A, Hilz, M.J, Platsch, G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Science 2000;175:3-12.
14. Goldstein DS, Holmes C, Cannon RO, 3rd, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 1997;336:696-702.
15. Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging 2008;52:378-387.
16. Boer CAA, Mocelin AJ, Matsuo T. Ewing's tests validation for autonomic dysfunction. Arq Neuropsiquiatr 1998;56:250-254.
17. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committe of American Autonomic Society and the American Academy of Neurology. Neurology 1996;46:1470.
18. Emre M, Aarsland D, Brow R. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.
19. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. 123Imetaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-194.
20. H Nagayama, M Hamamoto, M Ueda, J Nagashima, Y Katayama. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:249-251.
21. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
22. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale (UPDRS). In: Fahn S, Marsden CD, Calne DB, Goldstein M, (Eds). Recent developments in Parkinson's disease. New Jersey: Macmillan Health Care Information, 1987:153-164.
23. Agostini D, Carrio I, Verberne H. How to use myocardial 123I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging 2009;36:555-559.
24. Kashihara K, Ohno M, Kawada S, Okumura Y. Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 2006;47:1099-1101.
25. Ishibashi K, Saito Y, Murayama S, et al. Validation of cardiac (123)IMIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging 2010;37:3-11.
26. Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: A systematic review and metaanalysis. Parkinsonism Relat Disord 2012;18:494-500.
27. Fujishiro H, Frigerio R, Burnett M, et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 2008;23:1085-1092.
28. Sawada H, Oeda T, Yamamoto K, et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 2009;16:174-182.
29. Tateno F, Sakakibara R, Saiki A, Miyashita Y, Shirai K. Levodopa might affect metaiodobenzilguanidine myocardial accumulation. Mov Disord 2008;23:2097-2098.